June 4th 2023
Nirogacestat significantly reduced pain scores for patients with desmoid tumors.
C.R.U. Eye Symposium (Current, Relevant, Useful)
11/10/2023-11/12/2023
View More
C.R.U. Eye Symposium (Current, Relevant, Useful)
11/10/2023-11/12/2023
View More
C.R.U. Eye Symposium (Current, Relevant, Useful)
11/10/2023-11/12/2023
View More
Advances In™ Desmoid Tumors: Recognizing Disease Burden, Pathophysiology, and Targeted Treatments in Development
View More
BURST CME™: Taking ALS Management to the Next Level
View More
Taking Pompe Disease Management to the Next Level: Optimizing Clinical Assessments and Treatment Decision-Making
View More
7th Annual School of Nursing Oncology™
View More
Patient, Provider, and Caregiver Connection™: Incorporating the Patient Journey into HS Diagnosis and Management Practices
View More
The Latest on Acute Lymphocytic Leukemia
View More
A Focus on Acute Myeloid Leukemia
View More
Updates in Myelodysplastic Syndromes
View More
Patient, Provider, and Caregiver Connection™: Incorporating the Patient Journey into HS Diagnosis and Management Practices
View More
Patient, Provider, and Caregiver Connection™: Incorporating the Patient Journey into HS Diagnosis and Management Practices
View More
Clinical ConsultationsTM: Focusing on Fabry Disease in Females: Individualizing Diagnostic and Counseling Plans to Improve Long-Term Outcomes
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Better Diagnosing Is Needed in Sarcoma
November 21st 2020Pathology is the cornerstone of precision medicine, explained Marilyn M. Bui, MD, PhD, who added that, as a whole, the health care specialty needs to step it up in the diagnosis of sarcomas and the differentiation between the various histological subtypes.
PTC596 Granted Fast-Track Designations for Leiomyosarcoma, Glioma
November 19th 2020The FDA has granted a fast track designation and an orphan drug designation to the orally bioavailable small molecule tubulin-binding agent PTC596 for potential use in patients with leiomyosarcoma; the agent also received a rare pediatric disease designation and an orphan drug designation for potential use in patients with diffuse intrinsic pontine glioma (DIPG).
Pursuing Immunotherapy for Sarcoma Treatment
August 25th 2020Despite encouraging data shown in some subtypes, there is still a lot of work that still needs to be done with regard to determining the optimal use for immunotherapy in patients with sarcoma, a population that has historically been difficult to treat.
Expert Discusses Exciting Advancements in Sarcoma Treatment
April 30th 2020Though the use of next-generation sequencing (NGS) may not have immediate clinical implications for patients with sarcoma, it can provide valuable information for data collection and position patients for ongoing clinical trials that have the potential to push the needle forward, explained Gina Z. D'Amato, MD.
FDA Extends Review Period for Avapritinib to Treat GIST
February 8th 2020The FDA has extended the Prescription Drug User Fee Act deadline for a new drug application (NDA) for avapritinib (Ayvakit) as a treatment for adult patients with fourth-line gastrointestinal stromal tumor (GIST). The deadline, which was initially February 14, 2020, has been extended by 3 months to May 14, 2020, according to BluePrint Medicines, the developer of avapritinib.
Biomarkers Predict Osteosarcoma Treatment Response
February 2nd 2020The presence of the proteins p16 and p21 has shown to be predictive of treatment response in patients with osteosarcoma, a disease that previously had no identified biomarkers to indicate whether or not patients would benefit from therapy, explained C. Parker Gibbs, MD.
FDA Approves Tazemetostat for Epithelioid Sarcoma
January 24th 2020The FDA has granted an accelerated approval to tazemetostat (Tazverik) for the treatment of adult and pediatric patients aged ≥16 years old with metastatic or locally advanced epithelioid sarcoma that is not eligible for complete resection.
Trabectedin Now FDA-Approved for Metastatic Soft Tissue Sarcomas
October 23rd 2015Trabectedin (Yondelis) chemotherapy was approved by the FDA for treatment of patients with specific metastatic soft tissue sarcomas-liposarcoma and leiomyosarcoma-who previously received chemotherapy that included an anthracycline.